Clinical and Public Health Guidelines from the 2025 International symposium on breast diseases of inland São Paulo: strategies for early breast cancer detection and HER2-positive treatment within Brazil’s unified health system
Authors:
- Eduardo Carvalho PessoaEPEduardo Carvalho Pessoa
- Fabio BagnoliFBFabio Bagnoli
- Marcelo MadeiraMMMarcelo Madeira
- Joaquim Teodoro AraujoJAJoaquim Teodoro Araujo
- Giuliano ToselloGTGiuliano Tosello
- Beatriz GeronymoBGBeatriz Geronymo
- Daniel de Araujo ButtrosDBDaniel de Araujo Buttros
- André MattarAndré Mattar
- Renato TorresanRTRenato Torresan
- João Bosco Ramos BorgesJBJoão Bosco Ramos Borges
- Gil FacinaGFGil Facina
- Augusto Tufi HassanAHAugusto Tufi Hassan
Open Access
Abstract
Objective: To disseminate the clinical and public health policy consensus established during the 2025 International Symposium on Breast Diseases of Inland São Paulo, based on the voting of 110 expert panelists in breast oncology. Methods: Four priority topics were presented through evidence-based lectures, followed by anonymous electronic voting using a validated Delphi-based methodology. Consensus was defined as ≥75% agreement among panelists. Results: Consensus was achieved on prioritizing mammography screening from age 40 (80% agreement) and on the positive impact of interdisciplinary integration in early diagnosis (95% agreement). No consensus was reached on optimizing São Paulo’s High Suspicion Law (67% agreement) or on the tumor size cutoff for neoadjuvant chemotherapy in human epidermal growth factor receptor 2 (HER2)-positive breast cancer, with the majority (53%) favoring tumors >20 mm (T2N0). Conclusion: The symposium’s guidelines provide evidence-based recommendations to enhance breast cancer screening, early diagnosis, and treatment within Brazil’s Unified Health System (SUS). While consensus was reached on earlier screening and interdisciplinary integration, further discussion is needed to optimize the High Suspicion Law and standardize neoadjuvant therapy criteria. These findings have significant potential to improve patient outcomes and resource allocation in the SUS.Keywords
This publication has 9 references indexed in Scilit:
- Knowledge related to breast cancer screening programs by physicians in BrazilEinstein (São Paulo), 2024
- 10-year opportunistic mammographic screening scenario in Brazil and its impact on breast cancer early detection: a nationwide population-based studyJournal of Global Health, 2022
- Breast Cancer Treatment Delay in SafetyNet Health Systems, Houston Versus Southeast BrazilThe Oncologist, 2022
- Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021Annals of Oncology, 2021
- Análise de custo-efetividade de um painel genético no câncer de mama precoce na saúde suplementar brasileiraJornal Brasileiro de Economia da Saúde, 2021
- Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trialThe Lancet Oncology, 2020
- Patient‐reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancerCancer, 2020
- Effectiveness of Breast Cancer Screening: Systematic Review and Meta-analysis to Update the 2009 U.S. Preventive Services Task Force RecommendationAnnals of Internal Medicine, 2016
- Defining consensus: A systematic review recommends methodologic criteria for reporting of Delphi studiesJournal of Clinical Epidemiology, 2014